Fig. 2: Vaccine effectiveness against severe outcomes (hospitalization or death). | Nature Microbiology

Fig. 2: Vaccine effectiveness against severe outcomes (hospitalization or death).

From: Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario

Fig. 2

a–f, Adjusted vaccine effectiveness estimates of BNT162b2 (Pfizer-BioNTech Comirnaty), mRNA-1273 (Moderna Spikevax) and ChAdOx1 (AstraZeneca Vaxzevria) vaccines ≥14 d after the first dose (for individuals who received only one dose) and ≥7 d after the second dose against severe outcomes (hospitalization or death) caused by Alpha (a), Beta (b), Gamma (c), Beta/Gamma (d), Delta (e) and non-VOC (f) SARS-CoV-2 between 14 December 2020 and 17 August 2021 in Ontario, Canada; n = 7,438 test-positive Alpha, n = 174 test-positive Beta, n = 410 test-positive Gamma, n = 237 test-positive Beta/Gamma, n = 639 test-positive Delta and n = 6,371 test-positive non-VOC SARS-CoV-2 cases with severe outcomes (hospitalization or death), and n = 598,905 symptomatic test-negative controls. Data are presented as effectiveness point estimates, with error bars indicating the corresponding 95% CIs. Asterisks indicate vaccine effectiveness estimated as 100% on the basis of zero vaccinated test-positive cases.

Source data

Back to article page